Corcept Therapeutics Incorporated Stock Price and Value Analysis

Corcept Therapeutics Incorporated (NasdaqCM:CORT) in our automated value investing analysis, with the cash flow history and price comparison below.

Key Facts

Advertisement helps keep Trendshare free for most readers.

Hold-time calculator

Estimate how long you need to hold Corcept Therapeutics Incorporated to reach your target.

Target type

CORT Free Cash Flow Trend

Free Cash Flow trendline for CORT
Free Cash Flow trendline for Corcept Therapeutics Incorporated
CSV

Based on historical returns, we believe that Corcept Therapeutics Incorporated can grow its free cash at a rate of about 13%. That's positive!

AdvantagesDisadvantagesNeutral
  • This company is making money at a great rate!
  • This company is solid.
  • This company has wild ups and downs.
  • This stock looks overpriced.
  • This company pays no dividend.

Inside the CORT Numbers

CORT Price
(Corcept Therapeutics Incorporated stock price per share)
$64.98
[?] CORT Fair Price
(based on intrinsic value)
$6.78
[?] CORT Safety Price (based on a variable margin of safety) $4.41
Try your own return

The fair price above uses a 10.1% discount rate, the long-run US stock return (10.1% geometric, 1926 to 2025, from Bessembinder's working paper, updated 2026-11-09), and 2.5% terminal growth. A higher rate suits a higher return target and gives a lower value.

Value per share:

[?] PE Ratio versus Sector 141% higher than other Healthcare stocks
[?] PE Ratio versus Industry 58% lower than other Drug Manufacturers - General stocks
[?] Cash Yield 0.04%
[?] Free Cash Flow Jitter 53%

Insider Activity Summary

In the six months to 2026-11-21, no insider bought shares, and 7 insiders sold in 44 trades, about $38.4 million.

The six months before that had 0 buys and 14 sales.

Recent Insider Activity

Open-market buys and sells reported by Corcept Therapeutics Incorporated's officers, directors, and 10% owners on SEC Form 4. Routine transactions (tax withholding, option exercises, and stock grants) are excluded -- these are discretionary trades only.

Date Insider Type Shares Price
2026-08-04 Guyer William (Chief Development Officer) Sell 3,700 $113.12
2026-08-03 Lyon Joseph Douglas (See Remarks) Sell 1,540 $114.16
2026-08-03 Maduck Sean (See Remarks) Sell 20,305 $114.70
2026-07-30 Mokari Atabak (Chief Financial Officer) Sell 400 $108.46
2026-07-30 Mokari Atabak (Chief Financial Officer) Sell 15,477 $114.96
2026-07-30 Mokari Atabak (Chief Financial Officer) Sell 2,202 $110.03
2026-07-30 Mokari Atabak (Chief Financial Officer) Sell 4,700 $113.18
2026-07-30 Mokari Atabak (Chief Financial Officer) Sell 600 $110.95
2026-07-30 Mokari Atabak (Chief Financial Officer) Sell 8,956 $106.96
2026-07-30 Mokari Atabak (Chief Financial Officer) Sell 4,200 $105.54

This stock has short interest! This means that people have shorted it.

Why does that matter? They've made a bet that price will decrease from where they bought it. Maybe there are financial problems, or maybe there's a value play.

As of the latest analysis, there are 9,125,717 shares shorted. With 97,814,779 shares available for purchase and an average trading volume over the past 10 trading days of 1,181,290, it would take at least 7.7 days for all of the short holders to cover their shorts.

Related guides: good annual rate of return · high-yield stocks · forecasting earnings growth

Free Cash Flow by Fiscal Year

How to read this: free cash flow in plain terms, free cash flow jitter.

Each year names the SEC filer that reported it, so a change of filer shows up here.

Fiscal yearSEC filer (CIK)Free cash flow (USD millions)
2009 1088856 -18
2010 1088856 -22.3
2011 1088856 -27.4
2012 1088856 -36.1
2013 1088856 -37.1
2014 1088856 -27.5
2015 1088856 3
2016 1088856 18.3
2017 1088856 60.7
2018 1088856 115
2019 1088856 136
2020 1088856 151
2021 1088856 167
2022 1088856 120
2023 1088856 126
2024 1088856 197
2025 1088856 141

Download the yearly data as CSV.

Cash Conversion

How to read this: what free cash flow is, why earnings matter.

Over the 10 fiscal years from 2009 to 2025 with positive net income, operating cash flow totaled $1,238 million against net income of $974 million, or 1.27 times. Net income was negative in 7 of the 17 years, and those years are left out of the ratio.

In 2025, capital expenditures were $0.2 million, 0.1% of operating cash flow of $142 million, which leaves an estimated $142 million after capex. Across the 11 years with reported capex, it averaged 0.5% of operating cash flow. This uses that year's own capital expenditures, not the five-year average behind the free cash flow table, so the two can differ.

Fiscal yearNet income (USD millions)Operating cash flow (USD millions)Capital expenditures (USD millions)Operating cash flow / net income
2009 -20.2 -18 not reported n/a
2010 -26 -22.3 not reported n/a
2011 -32.4 -27.4 0 n/a
2012 -38 -36 0.2 n/a
2013 -46 -37.1 0.1 n/a
2014 -31.4 -27.4 0.2 n/a
2015 -6.4 3.1 0 n/a
2016 8.1 18.4 0.2 2.26
2017 129 60.9 0.4 0.47
2018 75.4 116 0.3 1.53
2019 94.2 136 1.1 1.45
2020 106 152 1.2 1.43
2021 113 168 0.5 1.49
2022 101 120 0.4 1.19
2023 106 127 0.1 1.19
2024 141 198 2.2 1.40
2025 99.7 142 0.2 1.42

Where the Cash Went

How to read this: why companies buy back shares, dividend yield explained.

Over the 5 fiscal years from 2018 to 2025 with dividend or share repurchase facts, estimated free cash flow totaled $741 million. That estimate uses the average of up to five years of capital expenditures, not each year's own, so it is not a reported figure.

In 5 of the 5 years, cash spent repurchasing shares was at least 5% of that year's estimated free cash flow, and in those years it totaled $253 million. Smaller amounts are left out of this sentence because they can be shares withheld to pay employees' taxes on stock awards.

In 2025, cash spent repurchasing shares was $173 million, 122.4% of estimated free cash flow of $141 million. That was more than the estimated free cash flow of the year.

Fiscal yearEstimated free cash flow (USD millions)Dividends paid (USD millions)Cash spent repurchasing shares (USD millions)Total returned (USD millions)Total as a percent of estimated free cash flow
2018 115 n/a 23.7 23.7 20.5%
2019 136 n/a 31 31 22.8%
2020 151 n/a 9.9 9.9 6.6%
2024 197 n/a 15.7 15.7 7.9%
2025 141 n/a 173 173 122.4%

Free cash flow here is an estimate: operating cash flow less the average of up to five years of capital expenditures. Cash spent repurchasing shares can include shares withheld to pay employees' taxes on stock awards. The entry n/a means the filings gave no usable figure, not that the amount was zero. Source: the company's annual reports to the SEC.

Revenue and Cash Margin

How to read this: earnings and margins.

Revenue was $0 million in 2009 and $761 million in 2025, a compound annual growth rate of 88.9% over 16 years. The starting revenue was under 10% of the latest, so that rate comes from a small base and says little about recent growth.

Revenue rose 12.8% from 2024 to 2025.

Our estimated free cash flow was $141 million in 2025, 18.6% of revenue. In 2009 the estimated margin was negative 61958.6%. This estimate charges each year with the average of up to five years of capital expenditures, so it is not the free cash flow the company reported.

Fiscal yearRevenue (USD millions)Estimated free cash flow (USD millions)Estimated free cash flow / revenue
2009 0 -18 -61958.6%
2016 81.3 18.3 22.5%
2017 159 60.7 38.2%
2018 251 115 45.9%
2019 306 136 44.3%
2020 354 151 42.8%
2021 366 167 45.7%
2022 402 120 29.8%
2023 482 126 26.1%
2024 675 197 29.2%
2025 761 141 18.6%

Balance Sheet

How to read this: how debt and assets are compared, the current ratio.

In 2025, cash and equivalents were $120 million against total liabilities of $189 million, or 63.8% of total liabilities. Total liabilities include everything the company owes, not only borrowed money.

Total liabilities were 22.6% of total assets in 2025, compared with 15.4% in 2010, an increase of 7.2 percentage points.

Stockholders equity was $648 million in 2025, compared with $21.2 million in 2010, a rise of 2949.4%.

Based on our estimated free cash flow, cash flow return on invested capital (CROIC) was 25.7% in 2025. Invested capital here is total assets less cash and current liabilities.

Fiscal yearTotal assets (USD millions)Cash and equivalents (USD millions)Total liabilities (USD millions)Stockholders equity (USD millions)
2010 25.1 24.6 3.9 21.2
2011 39.8 39.6 5 34.8
2012 99.2 93 37.4 61.8
2013 63.1 54.9 42.1 21
2014 34.6 24.2 38 -3.4
2015 51.9 40.4 33.4 18.5
2016 68.8 51.5 27.4 41.4
2017 221 31.1 29.6 191
2018 312 41.6 35.8 276
2019 412 31.3 41.1 371
2020 572 76.2 48.4 523
2021 424 77.6 48 376
2022 583 66.3 81.6 502
2023 622 136 115 507
2024 841 128 161 680
2025 837 120 189 648

What the Price Implies

How to read this: discounted cash flow, intrinsic value.

At today's price of $64.98, the price is above what our model can produce for average free cash flow growth between -30 and 60 percent a year, so no implied growth rate is shown. Our model assumes 13.3 percent a year for this stock. This is not a forecast of growth or a price target.

The table shows the same calculation at a price 20 percent lower and 20 percent higher than today's price, and the model's own growth rate at its fair price.

The model starts from the company's average free cash flow of $3.1 million, grows it over 10 years along the year-by-year growth path stored for this stock (the pace fades over the years, and the implied rate keeps that shape, so the rates here are 10-year averages), discounts it at 10.1 percent a year, adds a terminal value that grows 2.5 percent a year after year 10, adds the company's net worth, and divides by shares outstanding.

The baseline is the company's average free cash flow, and cyclical companies can mislead it.

CasePrice per shareAverage annual free cash flow growth
20 percent below the current price $51.98 above range
Current price $64.98 above range
20 percent above the current price $77.98 above range
Our model (stored fair price) $6.78 13.3%

Model assumptions: 10.1 percent discount rate, 2.5 percent terminal growth, 10 projection years. To try your own growth rate, use the intrinsic value calculator on this page. It uses a simpler single-rate model, so its results will not match the figures above exactly.

Price Versus Our Estimated Value

Positive free cash flow appears in 11 of the 17 fiscal years we hold for Corcept Therapeutics Incorporated from its current SEC filer.

Our fair value estimate for Corcept Therapeutics Incorporated is $6.78, below its current price of $64.98.

Year-to-year variability in free cash flow is volatile, measured at 53%.

No dividend yield is recorded for Corcept Therapeutics Incorporated in our data.

These figures are automated calculations from SEC filings and the recent price. They are not a recommendation to buy or sell. See how we estimate value.

Compared With Its Sector and Industry

How to read this: the price to earnings ratio.

Its trailing P/E ratio is 141% above the average for stocks in the Healthcare sector.

Its trailing P/E ratio is 58% below the average for stocks in the Drug Manufacturers - General industry.

A P/E ratio depends on trailing earnings, which one-time items can distort, so a lower P/E is not by itself evidence of value.

Closest Industry Peers

These are companies in the Drug Manufacturers - General industry, the ones closest in market capitalization to Corcept Therapeutics Incorporated, limited to companies whose pages we publish. The figures come from our latest data for each company.

CompanyMarket cap (USD millions)P/EDividend yieldCash yieldPrice versus our estimate
Corcept Therapeutics Incorporated (CORT) 7,112 48.9 - 0.0% 858% above
Alkermes plc (ALKS) 7,552 - - 1.5% 315% above
Prestige Consumer Healthcare (PBH) 2,352 15.3 - 7.8% 50% below
Perrigo Company plc (PRGO) 2,213 - 7.2% 72.9% 91% below
ANI Pharmaceuticals (ANIP) 1,558 13.9 - - 188% above
Elanco Animal Health Incorporated (ELAN) 12,866 - - - 96% above
Phibro Animal Health Corporation (PAHC) 1,352 13.9 1.4% - 82% above

Industry labels are approximate, and companies in one industry can run quite different businesses, so a peer may not be a close match.

Ratios on different fiscal calendars are not strictly comparable, and a trailing P/E can be distorted by one-time items.

SEC Filer History

Every fiscal year on this page is reported by one SEC filer, CIK 1088856.

Each figure on this page comes from that filer.

Risks to This Analysis

How to read this: understanding investment risk.

  • Free cash flow was negative in 6 of the 17 years we have.
  • Free cash flow is volatile from year to year, so the estimates depend heavily on which years are included.
  • These figures are automated calculations from SEC filings and the recent price. They may contain errors, and they do not reflect lawsuits, management changes, or other events the filings do not show.

How This Page Is Made

Latest annual report used
Fiscal year 2025
Price and market data last refreshed
2026-11-20
Model assumptions last reviewed
2026-11-09

Company figures come from the annual reports (Form 10-K) that each company files with the SEC, read from the SEC EDGAR company facts data. The share price and other market data come from a market data provider.

Free cash flow here is operating cash flow minus capital spending. To keep one unusual year from swinging the result, each year is charged with the average of up to five years of capital spending, so the figure is an estimate and not the free cash flow a company reports.

The fair price is the present value of ten years of projected free cash flow plus a terminal value, discounted at 10.1 percent a year, the long-run return of US stocks, with 2.5 percent growth after year ten. The figures on this page are estimates, not advice.

This analysis covers US companies that file 10-K annual reports. Free cash flow describes banks, real estate investment trusts and funds poorly, so treat their figures with extra caution. In the cash returned and balance sheet tables, a value of zero is treated as a gap in the data, not as a real zero.

Read the filings yourself: CORT annual reports (10-K) on SEC EDGAR. To try your own growth rate, use the intrinsic value calculator on this page. Our editorial standards explain how Trendshare handles its sources and corrections.

Advertisement supports free stock analysis content.

Questions to Answer Before You Invest in CORT

Does Corcept Therapeutics Incorporated have a coherent story? Does it have a plan to continue to make money? Is it worth your time? Only you can decide where to go from here. Our investment guide helps you ask the right questions, including how to buy stocks. Use these research links for more information.

Worked example: CORT

This example shows how we apply the Trendshare checklist to CORT: earnings power, cash generation, valuation, and margin of safety.

We check: business quality, free cash flow, P/E, and margin of safety.

  1. Step 1 — Snapshot

    • Price: 64.98
    • Market cap: $7.1B
    • EPS: 1.33
  2. Step 2 — Valuation checks

    • P/E: 48.857
    • FCF yield: 0.0%
    • Date checked: Nov 20, 2026
  3. Step 3 — Margin of safety

    • Compare price to fair value and safety price.
    • Look for durable cash generation and reasonable leverage.
    • Decide if it passes your personal checklist.